LRRK2 and Parkinson disease: Several inhibitors have undergone phase I and phase II clinical trials (Lewis, 2022), and a small-molecule LRRK2 kinase inhibitor developed by Denali Therapeutics and Biogen (DNL151/BIIB122, https://clinicaltrials.gov/ct2/show/NCT05418673) has progressed through to phase III efficacy trials for use in PD.